Plasma Protein Kallikrein-14 Strongly Predicts Pronounced Chromogranin A (CgA) Response in Small Intestinal Neuroendocrine Tumor (NET) Patients after Somatostatin Analog (SSA) Treatment: The Nordic EXPLAIN Biomarker Study Abstract #2083

Introduction: Predicting treatment response at an early stage in the treatment algorithm for NET is highly desirable.
Aim(s): To investigate 92 putative cancer-related proteins in plasma at the time of diagnosis and after 6 months of treatment in an attempt to explore new predictive biomarkers.
Materials and methods: One hundred small intestinal NET patients from 16 Nordic centers were prospectively followed. Blood samples were obtained before start of treatment, and 6 (±3) months after initiation of treatment. Plasma samples were analysed with Olink Proseek Multiplex Oncology II panel. Chromogranin A (CgA) was analysed centrally at Akademiska Lab Uppsala (NEOLISA Euro Diagnostica). Treatment response was analysed using a logistic regression model adjusted for the baseline CgA value and the baseline value of the biomarker.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Biomarkers
Presenting Author: Associate prof, Magnus Kjellman

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1694 Plasma Protein Fingerprinting for the Diagnosis of Small Intestinal Neuroendocrine Tumors (siNETs)
Introduction: siNETs are notoriously difficult to diagnose, especially in an early stage.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Biomarkers
Presenting Author: MD PhD Magnus Kjellman
#2783 Use of Plasma Proteins to Predict Progressive Disease in Patients with Small Intestinal Neuroendocrine Tumours
Introduction: Prediction of progression in small intestinal neuroendocrine tumors (SI-NET).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD PhD Roger Belusa
#672 Affinity Proteomic Plasma Analysis of Human Well-Differentiated Small Intestinal Neuroendocrine Tumors
Introduction: Small intestine neuroendocrine tumor (SI-NET) patients get diagnosis at the stage of metastasis and there is a lack of curative treatments.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Assoc. Prof, PhD Valeria Giandomenico
Authors: Darmanis S, Cui T, Li S C, Öberg K, ...
#152 Validation of a new assay that uses 2 monoclonal antibodies to measure intact and fragmented plasma CgA levels
Introduction: Plasma chromogranin A (CgA) levels are elevated in a variety of neuroendocrine tumors (NETs) and are used to aid in diagnosis, prognosis, and monitoring of treatment effects in NETs patients. We evaluated a newer sandwich ELISA assay (Cisbio US, Bedford, MA, USA) that utilizes two monoclonal antibodies that bind to the mid-region of the CgA protein and allow measurement of intact and fragmented circulating CgA. The results from the assay validation indicative of its overall robustness in terms of sensitivity, specificity, reproducibility, and stability are presented here.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Monica Motwani
#2967 Longitudinal Changes in Plasma 5-Hydroxyindoleacetic Acid (5-HIAA) and Other Biomarkers during Treatment of Functional Midgut Neuroendocrine Tumours (NETs) with Lanreotide Autogel: CALM NET Study Results
Introduction: CALM-NET (EudraCT 2013-002194-22; NCT02075606) evaluated pre-treatment circulating tumour cell levels in patients with NETs as a predictor of response to lanreotide autogel (LAN).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Dr Tahir Shah
Authors: Shah T, Caplin M, Khan M, Houchard A, ...